Blocking the PD-1/PD-L1 interaction has become an important
strategy
for tumor therapy, which has shown outstanding therapeutic effects
in clinical settings. However, unsatisfactory response rates and immune-related
adverse effects limit the use of anti-PD1/PD-L1 antibodies. Here,
we report the discovery and identification of S4-1, an
innovative small-molecule inhibitor of PD-L1. In vitro, S4-1 effectively altered the PD-L1/PD-1 interaction,
induced PD-L1 dimerization and internalization, improved its localization
to endoplasmic reticulum, and thus enhanced the cytotoxicity of peripheral
blood mononuclear cells toward tumor cells. In vivo, S4-1 significantly inhibited tumor growth in both
lung and colorectal cancer models, particularly in colorectal cancer,
where it led to complete clearance of a portion of the tumor cells.
Furthermore, S4-1 induced T-cell activation and inversed
the inhibitory tumor microenvironment, consistent with the PD-L1/PD-1
pathway blockade. These data support the continued evaluation of S4-1 as an alternative ICB therapeutic strategy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.